**Funding information**

This work was supported by research grants from the JSPS KAKENHI, Grant Numbers JP15K20353 (M.H.) and JP17H04237 (I.Y.); the Japan Agency for Medical Research and Development (AMED), JP17fk0108210 (I.Y.).

Introduction {#ams2443-sec-0004}
============

One of the endocannabinoids, N‐arachidonoyl ethanolamide (anandamide, AEA), is a lipid transmitter that has been implicated in the hypotension of septic shock. Anandamide is hydrolyzed to arachidonic acid (AA) and ethanolamine by fatty acid amide hydrolase (FAAH).[1](#ams2443-bib-0001){ref-type="ref"} Previously, we examined the expression of *FAAH* mRNA between septic patients and healthy controls. The expression of *FAAH* mRNA in septic patients was significantly lower than in healthy controls, and the expression level of *FAAH* mRNA remained at low levels in two non‐survivor cases, suggesting that the synthesis of FAAH, which is the lipid‐degrading enzyme of AEA, might presumably be involved in sepsis.

In this study, we analyzed the profiles of several fatty acids and their metabolites as well as the expression level of *FAAH* mRNA from patients during their septic status. The data obtained during the first week of sepsis revealed high levels of 9‐hydroxyoctadecadienoic acid (9‐HODE), 13‐HODE, 9,10‐dihydroxy‐12‐octadecenoic acid (9,10‐DiHOME), and 12,13‐DiHOME on day 1, and elevated prostaglandin E~1~ ethanolamide (PGE~1~‐EA) and decreased *FAAH* mRNA transcription level on day 7.

Case {#ams2443-sec-0005}
====

Five patients were admitted into the intensive care unit of Kindai University (Osakasayama, Japan) and treated before 2015; all patients met the diagnostic criteria of Sepsis‐3. All five patients were treated with polymyxin B‐immobilized fiber column‐direct hemoperfusion (PMX‐DHP) within 24 h of their admission followed by dialysis with continuous hemodiafiltration (CHDF) for \>7 days.

Various bioactive lipids in the plasma were measured using the LC/MS/MS Method Package for Lipid Mediators at Shimadzu Techno‐Research, Kyoto, Japan ([https:\\\\www.shimadzu.com\\an\\lcms\\lipid_mediators.html](https:\\www.shimadzu.com\an\lcms\lipid_mediators.html)). In total, 158 lipid mediators and internal standards were measured on days 1 and 7. The cut‐off value of each compound was a peak area of 3,000.

Whole blood RNA was used to quantify FAAH mRNA according to our previous report.[2](#ams2443-bib-0002){ref-type="ref"}

Results {#ams2443-sec-0006}
=======

The patient demographic data, the Sequential Organ Failure Assessment (SOFA) score, quick SOFA score, levels of *FAAH* mRNA expression, and AEA are listed in Table [1](#ams2443-tbl-0001){ref-type="table"}. Only case 5 died on day 21. The expression level of *FAAH* mRNA ratio (*FAAH* mRNA day 7/day 1) was 0.80 in case 5. The ratio in the fatal case 5 was lower compared to that of the survivor cases 1, 2, 3, and 4 with the ratios of 1.41, 5.64, 2.05, and 2.61, respectively. This indicates that the *FAAH* mRNA expression increased after 7 days among the survivors only.

###### 

Patient characteristics, severity, *FAAH* mRNA, and anandamide (AEA) level in five patients with sepsis

  Case   Gender   Age, years   Quick SOFA   SOFA score (excluding GCS)   *FAAH* mRNA   AEA   Cause of sepsis                                                  
  ------ -------- ------------ ------------ ---------------------------- ------------- ----- ----------------- ---------- ---------- ------ -------- -------- ---------------------------
  1      Male     47           ○            ○                                          2     5                 2.26E‐01   3.18E‐01   1.41   5,368    3,000↓   Severe acute pancreatitis
  2      Male     56           ○                                                       9     6                 6.49E‐02   3.66E‐01   5.64   41,893   4,662    Severe acute pancreatitis
  3      Male     66           ○                                                       7     7                 1.33E‐01   2.73E‐01   2.05   9,749    12,369   Wound infection
  4      Male     57                                                                   10    4                 2.28E‐01   5.95E‐01   2.61   14,981   7,542    Unknown
  5      Female   72           ○                                         ○             10    12                4.80E‐01   3.83E‐01   0.8    16,493   7,598    Gynaecological infection

GCS, Glasgow Coma Scale; SOFA, Sequential Organ Failure Assessment.
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The detected lipid mediators are described in Table [2](#ams2443-tbl-0002){ref-type="table"} and summarized in Figure [1](#ams2443-fig-0001){ref-type="fig"}. The selected lipid mediators met the criteria that the peak area observed in the fatal case was at least larger than the maximum peak area among the survivors. As a result, the following 12 lipid mediators were selected from the 158 compounds in the fatal case, as their peak area was higher compared to the other four survivor cases. On day 1, we selected: eicosapentaenoic acid (EPA) pathway, EPA (peak area of case 5 vs. maximum peak area of cases 1--4: 7,303 vs. ≤3,000); docosahexaenoic acid (DHA) pathway, DHA (245,904 vs. 87,971); linoleic acid (LA) pathway; 9‐HODE (110,625 vs. ≤3,000), 13‐HODE (329,746 vs. 6,806), 9,10‐DiHOME (229,402 vs. 7,738), and 12,13‐DiHOME (100,736 vs. 8,431); ALA pathway; 9‐HOTrE (10,263 vs. ≤3,000); AA pathway, AA (180,523 vs. 89,132), 5‐iPF2α‐VI (7,588,581 vs. 64,887); 11,12‐DHET (4,351 vs. ≤3,000), 20‐carboxy‐AA (17,650 vs. 6,047); ethanolamide; and PGE~1~‐EA (7,782 vs. ≤3,000). In contrast, on day 7, ethanolamide and PGE~1~‐EA were specifically detected in the fatal case (23,434 vs. ≤3,000); however, almost all of the lipid mediators were not specifically detected after PMX‐DHP and CHDF treatment. The levels of AEA on days 1 and 7 did not show any association with the septic status of the patients. In the fatal case, the peak area of AEA was 16,493, and 7,598 on days 1 and 7, respectively. In contrast, the peak area of the four survivors ranged from 5,368 to 41,893 and ≤3,000 to 12,369 on days 1 and 7, respectively.

###### 

Changes in lipid mediators on days 1 and 7 in five patients with sepsis

                       Survivors   Fatal case                                                                                                                         
  ---- --------------- ----------- ------------ ------- -------- ----------- -------- -------- ----------- --------- -------- --------- ------- ----------- --------- -------
  1    EPA             --          --                   --       --                   --       --                    --       --                7,303       3,076     0.322
  2    DHA             68,411      7,514        0.119   50,793   31,394      0.634    51,276   42,693      0.907     87,971   39,705    0.435   245,904     64,138    0.199
  3    9‐HODE          --          3,512                --       13,439      ↑        --       15,135      ↑         --       --                110,625     4,866     0.04
  4    13‐HODE         --          16,603       ↑       3,301    36,772      13.194   4,668    47,239      10.821    6,806    5,403     0.741   329,746     4,905     0.014
  5    9,10‐DiHOME     --          6,957        ↑       6,511    13,302      2.112    4,980    42,426      10.168    7,738    5,408     0.681   229,402     4,279     0.016
  6    12,13‐DiHOME    --          --                   8,431    7,333       0.899    6,634    24,178      4.35      6,585    5,411     0.8     100,736     5,233     0.043
  7    9‐HOTrE         --          --                   --       --                   --       --                    --       --                10,263      --        ↓
  8    AA              71,045      --           ↓       80,723   92,128      1.17     89,132   83,886      1.026     51,319   80,990    1.52    180,523     95,488    0.404
  9    5‐iPF2α‐VI      --          1,871,405    ↑       --       5,583,998   ↑        4,481    6,322,343   1,674.8   64,887   27,432    0.439   7,588,581   519,173   0.067
  10   11,12‐DHET      --          --                   --       --                   --       --                    --       --                4,351       --        ↓
  11   20‐carboxy‐AA   --          --                   6,047    --          --       --       --                    --       --                17,650      4,475     0.211
  12   PGE1‐EA         --          --                   --       --                   --       --                    --       --                7,782       23,434    2.155
  13   PGD2            --          --                   --       --                   --       --                    --       3,769     ↑       --          6,156     ↑
  14   PGF2a           --          --                   --       --                   4,046    --          ↓         --       6,317     ↑       --          4,623     ↑
  15   PGE2            --          --                   --       3,099       ↑        --       --                    3,215    14,025    4.489   --          6,349     ↑
  16   12‐HETE         --          3,465        ↑       5,382    96,102      21.162   4,019    29,268      7.874     23,701   154,556   5.920   25,393      45,915    1.444
  17   15‐HETE         --          --           --      --       --          --       --       --          --        --       7,455     ↑       --          --        --

↑Data only observed in day 7; ↓Data only observed in day 1; --, not detected; 5‐iPF2α‐VI, 5‐iso Prostaglandin F2α‐VI; 9‐HOTrE, 9‐hydroxyoctadecatrienoic acid; 11,12‐DHET, 11,12‐dihydroxy‐5Z,8Z,14Z‐eicosatrienoic acid; AA, arachidonic acid; DHA, docosahexaenoic acid; DiHOME, dihydroxy‐12‐octadecenoic acid; EPA, eicosapentaenoic acid; HETE, HODE, hydroxyoctadecadienoic acid; PGD2, prostaglandin D2; PGE1‐EA, prostaglandin E1 ethanolamide; PGE2, prostaglandin E2; PGF2a, prostaglandin F2a; TR, tendency ratio after compensation with internal standard (day 7 / day 1).
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![Comparison of lipid mediators of the fatal case (black circle) and survivors (white circles) of sepsis on day 1. 5‐iPF2α‐VI, 5‐iso Prostaglandin F2α‐VI; 9‐HOTrE, 9‐hydroxyoctadecatrienoic acid; 11,12‐DHET, 11,12‐dihydroxy‐5Z,8Z,14Z‐eicosatrienoic acid; AA, arachidonic acid; AEA, N‐arachidonoyl ethanolamide; DHA, docosahexaenoic acid; DiHOME, dihydroxy‐12‐octadecenoic acid; EPA, eicosapentaenoic acid; HODE, hydroxyoctadecadienoic acid; PGE1‐EA, prostaglandin E1 ethanolamide.](AMS2-6-413-g001){#ams2443-fig-0001}

Discussion {#ams2443-sec-0007}
==========

Bioactive lipid mediators play a crucial role in the induction and resolution of various pathophysiological states during infection. Among the various lipid mediators, LA and its metabolites are considered as important mediators during an infection. The HODEs are stable oxidation products of LA. Higher HODE concentrations are an indication of oxidative stress. Both 9‐HODE and 13‐HODE are known to possess the potential to bind to the peroxisome proliferator‐activated receptor‐γ,[3](#ams2443-bib-0003){ref-type="ref"} whereas 9‐HODE imparts a pro‐inflammatory effect through the G protein‐coupled receptor 132 (GPR132). In contrast, 13‐HODE cannot bind to GPR132 and its effects appear to be protective against inflammation.[4](#ams2443-bib-0004){ref-type="ref"}, [5](#ams2443-bib-0005){ref-type="ref"} Furthermore, the ratio of 13‐ to 9‐HODE, hydroxylated metabolites of LA, has been identified as a biomarker of immune status during influenza infection in mice.[6](#ams2443-bib-0006){ref-type="ref"}

The DiHOMEs are synthesized by soluble epoxide hydrolase from LA CYP450 metabolite epoxyoctadecanoic acids (EpOMEs). The EpOME levels are associated with acute respiratory distress syndrome, and DiHOMEs suppress the neutrophil respiratory burst.[7](#ams2443-bib-0007){ref-type="ref"},13‐DiHOME is a lipokine linked to metabolic homeostasis that increases the fatty acid uptake into the brown adipocytes through cold‐stress exposure.[8](#ams2443-bib-0008){ref-type="ref"}

In general, the dialysis membranes used in CHDF are not aimed to remove lipid mediators. The membrane pore size of the hemofilter used in CHDF only allows passage of substances with the molecular mass of 30,000--50,000.[9](#ams2443-bib-0009){ref-type="ref"} From the speculation from the aspect of molecular masses of LA metabolites (i.e. 9‐HODE is 296.44 and AEA is 347.53), LA metabolites and AEA can pass through the dialysis membrane and be removed as filtrate. However, if the lipid metabolites form a complex with the binding partners to become larger size than the pore, the lipid mediator complex cannot pass through the filter. It is reported that hemodialysis alters lipidomic profiles, including significant decreases of phosphatidylcholine, phosphatidylinositol, and high‐density lipoprotein cholesterol level, and the increase of sphingomyelin and diphosphatidylglycerol, of end‐stage renal failure patients.[10](#ams2443-bib-0010){ref-type="ref"} These analyses led us to anticipate that the hemodialysis might preferentially filter the lipid mediators. In our data, Table [2](#ams2443-tbl-0002){ref-type="table"} shows that, in the fatal case, various lipid mediators decreased, except for PGE~1~‐EA, whereas in survivor cases the ratios of some of the lipid mediators increased and became detectable on day 7. These data seemed to imply that the decrease of the LA metabolites in the fatal case is not the natural course of CHDF, but it might reflect the vital metabolic phenomenon. In order to elucidate the dynamics of hemofiltration on lipid mediators, further study will be needed.

As a consequence of the reduced expression of *FAAH* mRNA, the level of plasma AEA was supposed to be higher in the fatal case; however, the blood AEA level was not raised (Table [1](#ams2443-tbl-0001){ref-type="table"}). It is known that enzymes other than FAAH can metabolize AEA. Anandamide is a substrate for cyclooxygenase‐2 (COX‐2), lipoxygenases (12‐LOX and 15‐LOX), and P450, resulting in the formation of prostaglandin‐like compounds, prostamides.[11](#ams2443-bib-0011){ref-type="ref"} We analyzed prostaglandin D2, prostaglandin F2a, prostaglandin E2, and 12‐hydroxyeicosatetraenoic acid (HETE) and we found out that these analytes were elevated in the fatal case on day 7 (Table [2](#ams2443-tbl-0002){ref-type="table"}). In contrast, 15‐hydroxy‐eicosatetraenoic acid (15‐HETE), 5,6‐epoxyeicosatrienoic acid (5,6‐EET), 8,9‐epoxyeicosatrienoic acid (8,9‐EET), 11,10‐epoxyeicosatrienoic acid (11,10‐EET), and 14,15‐epoxyeicosatrienoic acid (14,15‐EET) were below the detection limit (data not shown). Based on these data, at least, COX‐2‐ and lipoxygenase‐mediated AEA degradation might account for the discrepancy of the *FAAH* mRNA and AEA level.

A systematic review and meta‐analysis of the randomized clinical trials revealed that nutritional supplementation with omega‐3 fatty acids (n‐3 FA) in septic patients reduced the length of stay in intensive care and the duration of mechanical ventilation; however, it did not affect the mortality.[12](#ams2443-bib-0012){ref-type="ref"} In our fatal case, the EPA and DHA levels were much higher than those of the four survivor cases. In this case, with the high level of n‐3 FA in the circulation system, the supplementation of n‐3 FA might not be effective in controlling the excessive immune responses.

There is a concept that the elimination of inflammatory substances, such as pro‐inflammatory cytokines and inflammatory lipid mediators, could be effective in sepsis treatment; however, the orchestration of each individual lipid mediator for its timing, duration, and magnitude is essential for homeostasis. A growing body of research has indicated that the convergence phase of inflammation needs anti‐inflammatory and proresolving lipid mediators as well as anti‐inflammatory cytokines.

This study is limited by its small sample size of only five Japanese cases. Further study with a larger sample size is needed to clarify the importance of LA metabolite profiling in the early stage of sepsis patients in Japan.
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